Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ) just unveiled an update.
CARsgen Therapeutics Holdings Ltd. announced the presentation of research results from a Phase Ib clinical trial of satricabtagene autoleucel (satri-cel) at the ESMO Congress 2025. Satri-cel is an autologous CAR T-cell product candidate targeting Claudin18.2-positive solid tumors, with a focus on gastric/gastroesophageal junction adenocarcinoma and pancreatic cancer. The trial results, which were presented as a poster, highlight the potential of satri-cel as a first-in-class treatment globally. The company has received various designations for satri-cel, including Priority Review and Breakthrough Therapy Designation in China, as well as Regenerative Medicine Advanced Therapy and Orphan Drug designations in the U.S., indicating significant progress and recognition in the field of CAR T-cell therapies.
The most recent analyst rating on (HK:2171) stock is a Sell with a HK$14.92 price target. To see the full list of analyst forecasts on CARsgen Therapeutics Holdings Ltd. stock, see the HK:2171 Stock Forecast page.
More about CARsgen Therapeutics Holdings Ltd.
CARsgen Therapeutics Holdings Ltd. is a biopharmaceutical company specializing in the development of innovative CAR T-cell therapies aimed at addressing unmet clinical needs in areas such as hematologic malignancies, solid tumors, and autoimmune diseases. The company has comprehensive capabilities in CAR T-cell research and development, including target discovery, preclinical research, clinical development, and commercial-scale production. CARsgen focuses on improving the safety and efficacy of CAR T-cell therapies while reducing treatment costs, with a mission to become a global leader in providing innovative cell therapies.
Average Trading Volume: 2,352,893
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.32B
For an in-depth examination of 2171 stock, go to TipRanks’ Overview page.